Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Toxicol Lett. 2011 Sep 25;206(1):105-11. doi: 10.1016/j.toxlet.2011.05.1035. Epub 2011 May 27.

Protection against nerve agent poisoning by a noncompetitive nicotinic antagonist.

Author information

  • 1Biomedical Sciences Department, Dstl Porton Down, Salisbury SP40JQ, Wiltshire, UK.

Abstract

The acute toxicity of organophosphorus (OP) nerve agents arises from accumulation of acetylcholine (ACh) and overstimulation of ACh receptors. The mainstay of current pharmacotherapy is the competitive muscarinic antagonist, atropine. Nicotinic antagonists have not been used due to the difficulties of administering a dose of a competitive neuromuscular blocker sufficient to antagonise the effects of excessive ACh, but not so much that it paralyses the muscles. An alternative approach would be to use a noncompetitive antagonist whose effects would not be overcome by increasing ACh concentrations. This study demonstrates that the compound 1,1'-(propane-1,3-diyl)bis(4-tert-butylpyridinium), which blocks open nicotinic ion channels noncompetitively, is able to reverse the neuromuscular paralysis after nerve agent poisoning in vitro and to protect guinea pigs against poisoning by nerve agents when used as part of a therapeutic drug combination including a muscarinic antagonist. In contrast to the oxime HI-6, this compound was equally effective in protecting against poisoning by sarin or tabun. Further studies should identify more effective compounds with this action and optimise doses for protection against nerve agent poisoning in vivo.

Crown Copyright © 2011. Published by Elsevier Ireland Ltd. All rights reserved.

PMID:
21641979
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk